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Abstract
Purpose Cilostazol (Pletal), a phosphodiesterase-3 inhi- bitor, was approved in the United States in 1999 to
reduce symptoms of intermittent claudication. Cyclic adenosine monophosphate levels increase from inhibition
of phos- phodiesterase resulting in anti-platelet, anti-inﬂammatory, and vasodilatory effects. Diabetes mellitus
is a chronic disease that causes endothelial and platelet dysfunction leading to both microvascular and
macrovascular compli- cations. This mini-review highlights the emerging evidence suggesting beneﬁts of using
cilostazol in treating micro- vascular complications associated with diabetes mellitus. Methods A review of
literature was conducted using PubMed and Embase databases focusing on cilostazol use in diabetes mellitus.
Results Cilostazol demonstrated renoprotective effects in patients with diabetic nephropathy by reducing serum
soluble adhesion molecule-1 and monocyte chemoattractant protein-1. Cilostazol’s anti-inﬂammatory actions
predictably attenuate glomerular damage from increased leukocyte adherence. Additionally, cilostazol delayed
renal dysfunc- tion secondary to type 2 diabetes mellitus as albuminuria was reduced most likely resulting from
inhibition of nuclear factor kappa-induced inﬂammatory and endothelial mar- kers. Cilostazol’s antiinﬂammatory actions in addition to its vasodilatory actions relieved retinal hypoxia and decreased excessive
production of retinal blood vessels suggesting beneﬁt in diabetic retinopathy. Cilostazol did not improve
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neuropathy symptom scores signifying that it may not be as beneﬁcial in patients with diabetic peripheral
neuropathy without diabetic nephropathy or diabetic retinopathy.
Conclusions Cilostazol’s pleiotropic effects may be bene- ﬁcial in patients with type 2 diabetes mellitus and
diabetic nephropathy. Additional, larger studies need to be con- ducted to assess the beneﬁts and risks of
using cilostazol as an alternative agent in treating patients with diabetic microvascular complications.
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Introduction
Cilostazol (Pletal), a phosphodiesterase-3 inhibitor, was approved in the United States in 1999 to reduce
symptoms of intermittent claudication. Prior to its approval in the United States market, cilostazol was
registered for 10 years in Japan [1]. Its off-label uses include secondary prevention of cerebrovascular
accident, coronary stent stenosis, and percutaneous coronary intervention. Patients with diabetes mellitus
have elevated platelet reactivity and cilostazol, combined with aspirin and clopidogrel, has been found to be
more effective in secondary prevention of cerebral infarction than aspirin and clopidogrel alone [2].
Compared with other antiplatelet agents, cilostazol was found to inhibit carotid intima-media thickness
progression in patients with type 2 diabetes mellitus, and therefore may be helpful in controlling carotid
atherosclerosis [3].
Phosphodiesterase (PDE) enzymes are grouped into eleven broad families, PDE-1 to PDE-11, based on
their various properties and structures. PDE-3 inhibitors can be further subdivided into PDE-3As and PDE3Bs. PDE-3As are found in platelets, vascular smooth muscle cells, and cardiac myocytes, while PDE-3Bs are
found in adipocytes, hepatocytes, pancreatic β cells, and macrophages [4]. By inhibiting PDEs, cyclic
adenosine monophosphate levels increase resulting in pleiotropic effects such as anti-platelet, antiinﬂammatory, and vasodilatory effects.
Diabetes mellitus is a chronic disease that causes endo- thelial and platelet dysfunction [5]. Endothelial
dysfunction develops with disease progression leading to both macro- vascular and microvascular
complications. Reduced angio- genesis in the brain, heart, and legs leads to macrovascular complications,
whereas excessive angiogenesis in the eye, kidney, and nerves causes microvascular complications [6].
Nontraditional uses of cilostazol have been explored as PDE-3s are found extensively throughout the body.
This mini-review highlights the emerging evidence suggesting beneﬁts of using cilostazol in treating
microvascular com- plications associated with diabetes mellitus.

Diabetic nephropathy
Diabetic nephropathy can cause end-stage renal disease and is characterized by proteinuria with early increases
in urinary albumin levels [7, 8]. Reactive oxygen species, induced by hyperglycemia, cause both direct and
indirect endothelial damage by modifying extracellular matrix pro- teins and by escalating the inﬂammatory
response [9, 10]. Nuclear factor kappa B is triggered by reactive oxygen species and induces monocyte
chemotactic protein-1 (MCP- 1), a pro-inﬂammatory chemokine, which contributes to renal deterioration by
recruiting macrophages [11–14].
In a randomized, placebo-controlled trial, cilostazol was evaluated in 90 Taiwanese patients with diabetic
nephro- pathy and peripheral arterial occlusion disease [15]. The effects of cilostazol in delaying renal
dysfunction secondary to type 2 diabetes mellitus were assessed through changes in urinary microalbuminuria
(MAU) and albumin-to-creatinine ratio (ACR). Only patients with type 2 diabetes mellitus with an A1C
between 7.0 and 12.0% were included in the study and were given either oral cilostazol 100 mg twice daily (n

= 45) or placebo (n = 45) for 52 weeks. Partici- pants were subdivided into two groups based on baseline
values: MAU (ACR 30–300 μg/mg) or macroalbuminuria (ACR > 300 μg/mg). The average age, duration of
diabetes, and baseline A1C values were similar between groups. Patients in the cilostazol-treated group had a
greater body- mass index, were more likely to smoke, and more likely to take statins, ACE-Is/ARBs, and
aspirin. After 52 weeks of treatment, cilostazol reduced albuminuria (p = 0.024) and subsequently reduced the
ACR (p = 0.02) compared with placebo; however, the values were only marginally reduced in patients with
MAU (p = 0.06) after subdivision. A regression analysis found that changes in albuminuria and ACR were
associated with notable changes in inﬂammatory and endothelial markers, suggesting that cilostazol exhibits
protective effects through its anti-inﬂammatory actions. Treatment with cilostazol signiﬁcantly reduced the
inﬂam- matory marker highly-sensitive C-reactive protein (p = 0.03), endothelial markers E-selectin (p <
0.001) and solu- ble vascular cell adhesion molecule-1 (p < 0.001). Results of the study suggest that renal
deterioration resulting from an upregulated immune response mediated by NF-ĸB-induced inﬂammatory and
endothelial markers may be suppressed with cilostazol by inhibiting NF-ĸB [15–17]. Additionally, as
supported by another study, cilostazol may ameliorate peripheral arterial occlusion disease, a macro- vascular
complication of diabetes mellitus, in patients with type 2 diabetes mellitus by attenuating pro-inﬂammatory
markers [18].
The renoprotective effects of cilostazol in diabetic nephropathy were demonstrated in another study [19].
Jiao et al. measured changes in serum soluble adhesion molecule-1 (sICAM-1) and MCP-1 levels in patients
with type 2 diabetes mellitus with and without early diabetic nephropathy. Early nephropathy was deﬁned as
a urinary albumin excretion rate level between 30 and 300 mg/24 h. Participants were divided into three
groups with the ﬁrst group (Group A) consisting of 20 subjects without protei- nuria. Forty participants with
early diabetic nephropathy were evenly divided into the second (Group B) and third groups (Group C).
Subjects in Group B received cilostazol 100 mg twice daily, while subjects in Group C received placebo.
Treatment lasted for 6 months and participants were not to take aspirin, other antiplatelet agents, anticoagulants, or vasodilators during the study period. Prior to the start of the study, the sICAM-1 levels in the
three groups were: Group A 214.5 + 94.6 ng/mL, Group B 450.0
+ 100.7 ng/mL, and Group C 422.0 + 422.9 ng/mL.
Patients with early diabetic nephropathy had higher baseline levels of sICAM-1, suggesting that the
occurrence of dia- betic nephropathy is associated with increased levels of sICAM-1 causing glomerular
damage from increased leu- kocyte adherence [20, 21]. After treatment with cilostazol, sICAM-1, MCP-1,
and urinary albumin excretion rate decreased signiﬁcantly (sICAM-1 285.1 + 94.4, p < 0.01) compared with
treatment with placebo (sICAM-1 412.3 + 89.6). Additional measures in the study included blood pressure,
liver and kidney function, and HbA1c; however, no signiﬁcant changes were observed after treatment with
cilostazol.
Together, the results from both studies demonstrate that the proposed mechanism of action by which
cilostazol ameliorates the progression of renal dysfunction in patients with diabetic nephropathy is through
reduced
inﬂammation.

Diabetic retinopathy
Diabetes-induced retinal neurodegeneration results from increased vascular permeability and disordered retinal angiogenesis
[7]. Glucose toxicity causes endothelial dys- function, which increases permeability allowing circulating macrophages and
pro-inﬂammatory cytokines to enter and cause neuronal damage [22]. Both hyperglycemia and hypoxia damage the
endothelium by triggering cells to produce signal proteins such as vascular endothelial growth factor (VEGF) [23, 24].
Current treatments for diabetic retinopathy focus on inhibiting VEGF since overproduction results in disordered
angiogenesis [25]. However, reducing rather than blocking VEGF may be an alternative strategy since VEGF initially
protects cells by re-establishing oxy- gen delivery [25].
In a preclinical study performed in rats, the effects of oral cilostazol (30 mg/kg) on retinal neurodegeneration were
compared with 0.9% saline solution [24]. Diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats and matched
nondiabetic Long-Evans Tokushima Otsuka (LETO) control rats were treated daily for 15 weeks with either cilostazol or
placebo. Glial ﬁbrillary acidic protein immunostaining and VEGF immunoreactivity demonstrated that cilostazol treat- ment
improved retinal stress and ischemia, respectively. Retinal glial ﬁbrillary acidic protein and VEGF protein levels decreased
in both OLETF and LETO rats with cilostazol treatment; however, levels decreased signiﬁcantly only in OLETF rats.
Cilostazol was also able to signiﬁcantly reduce retinal ganglion cell death in OLETF diabetic rats, suggesting that it may
protect against diabetic retinopathy.
As demonstrated in the study, cilostazol’s vasodilatory properties relieve hypoxia by improving ischemia and its antiinﬂammatory properties reduce excessive production of blood vessels by decreasing VEGF expression. Human studies need
to be conducted to support these results to further evaluate cilostazol’s effect in protecting against neuronal damage and
prevent vision loss in patients with diabetes.
Diabetic neuropathy
In a small pilot study, cilostazol (100, 200 mg/day) was compared with placebo to evaluate changes in neuropathy symptom
scores (NSS) in Filipino patients with type 2 diabetes mellitus and with diabetic peripheral neuropathy [26]. Neuropathy was
diagnosed through the accordance of two neurologists and was assessed by comparing patient- reported NSS taken at
baseline, week 4, week 8, and week
12. Additionally, walking distance and walking speed were assessed using a Walking Impairment Questionnaire. Patients
were divided into three groups: 15 patients treated with placebo, 16 patients treated with cilostazol 100 mg/day,

and 16 patients treated with cilostazol 200 mg/day. Patients included in the study were diagnosed with type 2 diabetes
mellitus more than 3 months prior to start of the trial, were in good glycemic control (HbA1c ≤ 8%), and were maintained on
their diabetes medications during the study period. The mean age between treatment groups was 56 years with a greater
proportion of women in each treatment group. Patients in the placebo-treated group were on average hea- vier, while
patients in the low-dose cilostazol treatment group were diagnosed with diabetes for a longer period of time. Although
overall NSS did improve from baseline to
12 weeks, there were no signiﬁcant differences in NSS between treatment groups (at 12 weeks, p = 0.333). Walking speed
improved signiﬁcantly (p = 0.028) with low-dose cilostazol treatment suggesting improved peripheral blood ﬂow. The
most common reported adverse events at week 4 were headaches (12 patients) and palpitations (8 patients); however, these
side effects were not reported at week 12 of the study. Out of the 12 patients that reported headaches, three were receiving
placebo, four were receiving low-dose cilostazol, and ﬁve were receiving high-dose cilostazol. Results from this study did
not demonstrate signiﬁcant improvement in relieving the symptoms of diabetic neuro- pathy with cilostazol therapy.
However, increased walking speed in the low dose-treated cilostazol group suggests potential beneﬁt in patients with
diabetes.
Adverse reactions
In the trials reviewed above, cilostazol did not change body mass index, hemoglobin A1c, fasting glucose, and anklebrachial index [8, 15, 24, 26]. Since blood glucose levels were not improved, good glycemic control in patients with
diabetes is essential and is likely the rationale for appro- priate glycemic control as an inclusion criterion [15, 26]. In the
Tang et al. study, two patients withdrew due to severe dizziness in the cilostazol-treated group, while in the Rosales et al.
study patients treated with cilostazol experi- enced more headaches and palpitations, however, these side effects
disappeared after week 8 [26]. The risks and beneﬁts of initiating and continuing cilostazol should be evaluated for each
patient especially in patients with a history of angina, cardiac arrhythmias, and uncontrolled hypertension [27]. Dizziness,
headaches, and palpitations are common adverse reactions related to cilostazol as well as are diar- rhea, pharyngitis, and
rhinitis [27]. Furthermore, because of cilostazol’s potential to induce palpitations and tachyar- rhythmia, its use is
contraindicated in patients with con- gestive heart failure [27]. Serious adverse reactions include atrial ﬁbrillation, cardiac
arrest, myocardial infarction, and ventricular tachycardia, as well as bleeding and hemorrha- ging [27]. In a case report
including three patients, a potential
relationship
between cilostazol-induced

tachycardia and hyperglycemia was observed [28]. All three patients had a past medical history of type 2 diabetes and were
admitted for cerebral infarction. Cilostazol was initiated in each patient to prevent a subsequent cerebral infarction. All three
patients had an elevated HbA1c and included an HbA1c of 10.7, 10.3, and 9.3% upon admission for patients 1, 2, and 3,
respectively. Two out of the three patients were switched from cilostazol to clopidogrel as their heart rates increased
following cilostazol initiation. Notable decreases in heart rate and blood glucose were noted in both patients following drug
substitution. Patient 2 beneﬁted from an increase in heart rate as he had sinus bradycardia with ﬁrst degree atrioventricular
block and therefore continued cilos- tazol. The effects of cilostazol on glycemic control require further investigation as the
studies above did not show a change in fasting glucose and hemoglobin A1c. However, all patients included in the studies had
good glycemic control unlike the three patients included in the case report. For patients without good glycemic control,
cilostazol initiation may not be appropriate and if initiated, then close monitoring to adjust diabetes medications may be
necessary.

Conclusion
Cilostazol shows potential beneﬁt in treating microvascular diabetic complications such a diabetic nephropathy. It is
important to keep in mind that most of the clinical studies evaluating cilostazol’s effects were conducted primarily in Asian
populations with a small number of subjects. While evidence exists, further studies in more diverse, human populations need
to be conducted to fully evaluate cilosta- zol’s therapeutic potential in ameliorating diabetic micro- vascular complications.
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